Pneumonia and procalcitonin levels: refining outcome prediction
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
- Serial procalcitonin (PCT) measurement in patients with pneumonia shows promise for predicting adverse clinical outcomes.
Why this matters
- Largest study in North America evaluating prognostic potential of serial PCT in hospitalized patients with community acquired (CAP) or healthcare-associated pneumonia (HCAP).
- Prospective cohort study of patients hospitalized with CAP or HCP.
- PCT was measured on days 1-4.
- Composite adverse outcome endpoints were all-cause mortality, ICU admission, and bacteremia.
- Funding: bioMérieux.
- 317 patients with CAP or HCAP.
- 25% met the composite primary endpoint.
- Patients with CAP requiring ICU-level care had significantly elevated PCT values on days 1 and 2, as opposed to days 3 and 4 ...